Sanofi Consumer Healthcare Intrinsic Value
Sanofi Consumer Healthcare (SANOFICONR) median intrinsic value is ₹1613.36 from 9 valuation models (range ₹807–₹2541), vs current price ₹4033.40 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Check SANOFICONR market value to track the company's total market size over time.
SANOFICONR Valuation Methods Summary — DCF, Graham Number & P/E
Sanofi Consumer Healthcare intrinsic value across 9 models vs current price ₹4033.40 — upside/downside and value range per method. For current market price and key ratios, visit Sanofi Consumer Healthcare share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹2541.00 | ₹2032.80 - ₹3049.20 | -37.0% | EPS: ₹115.50, Sector P/E: 22x |
| Book Value Method | asset | ₹806.68 | ₹726.01 - ₹887.35 | -80.0% | Book Value/Share: ₹166.96, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1210.02 | ₹1089.02 - ₹1331.02 | -70.0% | Revenue/Share: ₹421.30, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1617.39 | ₹1455.65 - ₹1779.13 | -59.9% | EBITDA: ₹372.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1613.36 | ₹1290.69 - ₹1936.03 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1596.65 | ₹1436.99 - ₹1756.32 | -60.4% | EPS Growth: 17.3%, Fair P/E: 13.8x |
| Growth Adjusted P/E | growth | ₹1862.44 | ₹1676.20 - ₹2048.68 | -53.8% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| ROE Based Valuation | profitability | ₹2016.70 | ₹1815.03 - ₹2218.37 | -50.0% | ROE: 69.3%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1210.02 | ₹1089.02 - ₹1331.02 | -70.0% | EPS: ₹115.50, BVPS: ₹166.96 |
SANOFICONR Intrinsic Value vs Market Price — All Valuation Models
Sanofi Consumer Healthcare fair value range ₹807–₹2541 vs current market price ₹4033.40 across 9 valuation models. See SANOFICONR price book multiple to compare market price against book value per share.
SANOFICONR Intrinsic Value Analysis — Undervalued or Overvalued?
Sanofi Consumer Healthcare median intrinsic value ₹1613.36, current price ₹4033.40 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of SANOFICONR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Sanofi Consumer Healthcare (SANOFICONR) is ₹1613.36 (median value). With the current market price of ₹4033.40, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹806.68 to ₹2541.00, indicating ₹806.68 - ₹2541.00.
Is SANOFICONR undervalued or overvalued?
Based on our multi-method analysis, Sanofi Consumer Healthcare (SANOFICONR) appears to be trading above calculated value by approximately 60.0%.
SANOFICONR Financial Health — Key Ratios vs Industry Benchmarks
Sanofi Consumer Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 14.11 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 69.3% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 37.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.77x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
SANOFICONR Cash Flow Quality — Operating & Free Cash Flow
Sanofi Consumer Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹175 Cr | ₹175 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹439 Cr | ₹439 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |